Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder,Joshua Richter,Naresh Bumma,Jason Brayer,James E. Hoffman,William I. Bensinger,Ka Lung Wu,Linzhi Xu,Dhruti Chokshi,Anita Boyapati,Damien Cronier,Yariv Houvras,Karen Rodriguez Lorenc,Glenn S. Kroog,Madhav V. Dhodapkar,Suzanne Lentzsch,Dennis Cooper,Sundar Jagannath

Clinical Lymphoma Myeloma and Leukemia（2022）

Cited 0|Views11
No score
Abstract
REGN5458 shows early, deep, and durable responses with a manageable safety profile in triple or greater-refractory patients with RRMM. This study is funded by Regeneron.
More
Translated text
Key words
MM,clinical trial,bispecific antibody,multiple myeloma,Phase I/II
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined